QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-equal-weight-on-galapagos-maintains-38-price-target

Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.

 galapagos-plans-clinical-and-translational-data-presentations-at-ebmt-congress-2024

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...

 galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress-analyst

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded m...

 b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

 b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

 morgan-stanley-assumes-galapagos-at-equal-weight-announces-price-target-of-38

Morgan Stanley analyst Judah Frommer assumes Galapagos (NASDAQ:GLPG) with a Equal-Weight rating and announces Price Target o...

 earnings-scheduled-for-february-22-2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

 galapagos-to-present-new-preliminary-translational-data-and-previously-disclosed-data-from-euplagia-1-phase-12-study-at-the-european-society-for-blood-and-marrow-transplantation---8k

The preliminary translational data demonstrate that Galapagos’ differentiated point-of-care manufacturing platform offers the p...

 european-drugmaker-galapagos-collaborates-with-biotech-bridgene-biosciences-to-develop-cancer-treatments

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...

 b-of-a-securities-maintains-neutral-on-galapagos-raises-price-target-to-44

B of A Securities analyst Jason Gerberry maintains Galapagos (NASDAQ:GLPG) with a Neutral and raises the price target from $...

 galapagos-transforms-into-biotech-innovator-sells-jyseleca-business-to-alfasigma-with-key-executive-transition

In connection with the transaction, Galapagos expects to realize substantial savings ranging between €150 million and €200 mill...

 galapagos-nv-announced-that-the-first-patient-has-been-dosed-in-papilio-1-the-phase-12-study-to-evaluate-the-safety-efficacy-and-feasibility-of-glpg5301-in-adult-patients-with-relapsedrefractory-multiple-myeloma

GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate, administe...

 galapagos-to-present-new-data-at-ash-2023-from-ongoing-cd19-car-t-studies-with-glpg5201-and-glpg5101

Galapagos NV ((Euronext &, NASDAQ:GLPG) to present additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION